ProCE Banner Series

Addressing Key Questions: Expert Insights to Guide Pathologist-Informed Clinical Decisions in HER2-Expressing or Amplified Solid Tumors

Join us for this interactive symposium in conjunction with USCAP 2024 in which a panel of pathologists and medical oncologists will discuss the nuances of HER2 testing across solid tumors and the impact of testing results on treatment selection.

  AMA
Who Should Attend

This educational program is intended for pathologists and other healthcare professionals involved in precision care of HER2-altered solid tumors.

All Events

Addressing Key Questions: Expert Insights to Guide Pathologist-Informed Clinical Decisions in HER2-Expressing or Amplified Solid Tumors

Past Events

March

26

2024

6:30 AM - 7:30 AM Eastern Time (ET)

In-personVirtual

Hilton Baltimore Inner Harbor, 401 W Pratt St., Baltimore, Maryland 21201

Faculty

ProCE Banner Faculty
Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

ProCE Banner Faculty
Katherine M. Bever, MD

Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

ProCE Banner Faculty
Laura C. Collins, MD

Vice Chair of Anatomic Pathology
Director of Breast Pathology
Beth Israel Deaconess Medical Center
Professor of Pathology
Harvard Medical School
Boston, Massachusetts

ProCE Banner Faculty
Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

ProCE Banner Faculty
Alexander Craig Mackinnon, Jr., MD, PhD, MSHA

Robert B. Adams Endowed Professor
Professor and Director, Division of Genomic Diagnostics & Bioinformatics
Department of Pathology
The University of Alabama at Birmingham Heersink School of Medicine
Birmingham, Alabama

ProCE Banner Faculty
Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
Professor, Divisions of Cancer Medicine and Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

ProCE Banner Faculty
Elizabeth D. Thompson, MD, PhD

Associate Professor of Pathology and Oncology
Division of Surgical Pathology
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Topics

Oncology

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence and competence, of learners to accurately perform pathological assessment, diagnose and provide evidence-based treatment strategies for patients with HER2-altered solid tumor malignancies.

Target Audience
This educational program is intended for pathologists and other healthcare professionals involved in precision care of HER2-altered solid tumors. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement pathological procedures to identify patients who may benefit from HER2-targeted therapy through proper understanding of HER2 status across solid tumors, and the use of guideline and expert recommended testing
  • Summarize the importance of proper HER2 evaluation through consideration of current and emerging clinical trial data and recent FDA approved indications with HER2-targeted therapies
  • Collaborate with the multidisciplinary team to reduce barriers to pathological assessment and optimize therapeutic strategies for patients with HER2-altered solid tumors

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

American Board of Pathology Continuous Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning point in the American Board of Pathology’s Continuing Certification Program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

For ABPath Lifelong Learning points, your information will be shared with the ABPath through CCO’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your Lifelong Learning points to appear on your ABPath records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, and Seagen.